卵巢上皮性癌组织Seprase蛋白表达及其预后意义的研究  

Protein and mRNA expressions of Seprase in epithelial ovarian carcinoma

作　　者：张梦真[1] 乔玉环[1] 索振河 

机构地区：[1]郑州大学第一附属医院妇产科,河南郑州450052 [2]河南省高校临床医学重点开放实验室,河南郑州450052

出　　处：《中华肿瘤防治杂志》2010年第4期285-289,共5页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:检测卵巢上皮性癌组织中Seprase蛋白和mRNA的表达及预后意义。方法:分别采用免疫组化和原位杂交技术检测378例卵巢上皮性癌石蜡包埋组织中Seprase蛋白和86例组织mRNA的原位表达,12例正常卵巢组织作对照。结果:378例卵巢癌组织中,Seprase蛋白免疫组化阳性表达336例。12例正常卵巢组织中,Se-prase阳性4例。正常卵巢和卵巢癌组织中,Seprase蛋白阳性表达率分别为33.3%和88.9%,两组之间差异有统计学意义,χ2=32.12,P=0.001。Seprase蛋白的表达与卵巢癌组织学分级和类型及临床分期有关,而与患者年龄无关,与患者预后呈负关(P=0.033)。86例卵巢癌组织SeprasemRNA的表达阳性率为96.5%(83/86),显著高于其在正常卵巢组织的16.66%(2/12),P<0.01。SeprasemRNA和蛋白表达一致,rs=0.48,P=0.001。结论:Se-prase蛋白在卵巢癌的发生发展中起一定作用,并可能成为其预后因素。OBJECTIVE：To evaluate the expression of Seprase in patients with epithelial ovarian carcinoma（EOC）and its clinical values.METHODS：Immunohistochemistry（IHC）was used to examine the expression of Seprase protein in a series of 378 formalin-fixed paraffin-embedded tissues from patients with EOC.Additionally,86 tissues were investigated for the mRNA expression by in situ hybridization（ISH）by using specific FITC-labeled RNA probes.Twelve normal ovaries were also studied as controls.RESULTS：The positive staining of Seprase protein was observed in 336（88.9%）of 378 patients with EOC while only 4（33.3%）cases were weak stained in 12 normal ovary tissues by IHC（χ2=32.12,P=0.001）.Seprase protein expression was associated with the FIGO stage,histological grade and type.The increased levels of Seprase were significantly associated with a shorter overall survival（P=0.033）.Of 86 patients,96.5%（83/86）were positively stained for Seprase mRNA which was significantly higher than that in normal tissues（16.66%,2/12,P0.01）.The seprase mRNA expression was correlated with the corresponding protein（rs=0.48,P=0.001）.CONCLUSION：This finding indicates that Seprase may be involved in the development of ovarian cancer and a potential prognostic marker for epithelial ovarian carcinoma.

关 键 词：卵巢肿瘤 明胶酶类 原位杂交 RNA 信使 免疫组织化学 

分 类 号：R737.31[医药卫生—肿瘤]